Zipalertinib Hits Primary Endpoint in Lung Cancer Trial as Biotech Catalyst Season Delivers Mixed Reads
Positive pivotal data in EGFR exon 20 lung cancer lands alongside Definium's Phase 3 Voyage topline in generalized anxiety disorder and a dense slate of clinical-stage earnings calls from Allogene and Inovio.
Zipalertinib met its primary endpoint in a lung cancer study, delivering a clean pivotal readout into an unusually crowded biotech catalyst window that also featured Definium Therapeutics' Phase 3 Voyage results for DT120 and quarterly updates from Allogene and Inovio.
BREAKING STORYBULLISH